Levetiracetam Aurovitas (Levetiracetam)

• Levetiracetam is an anticonvulsant used to control various seizure types in epilepsy.
• Partial‑onset seizures: reduces the frequency of focal seizure episodes.
• Primary generalized tonic‑clonic seizures: helps prevent generalized convulsive episodes.
• Myoclonic seizures: diminishes rapid, involuntary muscle jerks associated with myoclonic epilepsy.

• Levetiracetam binds to the synaptic vesicle protein SV2A, modulating neurotransmitter release and stabilizing neuronal membranes. This action reduces neuronal hyperexcitability and suppresses the propagation of seizure activity across the central nervous system.

Levetiracetam may cause a range of adverse reactions, from mild to serious.

Common Side Effects

• Dizziness: transient sensation of light‑headedness.
• Fatigue: feeling unusually tired or weak.
• Somnolence: increased sleepiness during the day.
• Headache: mild to moderate cranial pain.
• Irritability: mood changes or increased agitation.
• Nausea: upset stomach or feeling of queasiness.

Serious or Rare Side Effects

• Severe allergic reactions: rash, swelling, or difficulty breathing.
• Mood alterations: depression, anxiety, or suicidal thoughts.
• Blood disorders: leukopenia or thrombocytopenia.
• Stevens‑Johnson syndrome: rare, severe skin reaction.
• Hepatic dysfunction: elevated liver enzymes.
• Respiratory depression: marked reduction in breathing effort.

Before initiating therapy, consider patient‑specific factors and monitor appropriately.

• Renal impairment: adjust dose based on renal function.
• Hepatic impairment: monitor liver function tests regularly.
• History of psychiatric disorders: observe for mood changes or suicidal ideation.
• Pregnancy: risk unknown; use only if potential benefit justifies the risk.
• Concomitant alcohol use: avoid excessive intake as it may increase sedation.
• Store at room temperature: keep in the original packaging, protect from moisture and light.

Levetiracetam can interact with several medications, requiring careful management.

Major Interactions (Avoid)

• Carbamazepine: may reduce levetiracetam plasma concentrations.
• Phenobarbital: can lower levetiracetam levels.
• Phenytoin: may decrease levetiracetam exposure.
• Valproic acid: may increase levetiracetam concentrations.
• Other antiepileptics: potential additive central nervous system effects.

Moderate Interactions (Monitor Closely)

• Oral contraceptives: efficacy may be reduced.
• Antidepressants: monitor for mood alterations.
• Alcohol: may potentiate sedation and dizziness.